Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine

NCT03284710 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

132

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: ALVAC-HIV (vCP2438)
BIOLOGICAL: Bivalent Subtype C gp120/MF59
BIOLOGICAL: Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension
BIOLOGICAL: Bivalent Subtype C gp120

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]
[object Object]
[object Object]